Stockreport

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Inc.  (AIM) 
PDF Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference [Read more]